ROR1 CAR T / Miltenyi Biomedicine, Miltenyi Biotec - LARVOL DELTA

Armoring ROR1 CAR T cells with IL18 improves CAR T cell function and cytotoxicity against pancreatic cancer cell-lines in vitro and in vivo (AACR 2026) - "This armoring strategy may offer a promising approach solid tumor indications and warrants further preclinical and translational investigation.ABFig 1. In vivo demonstration of effective constitutive and inducible IL18 armoring of ROR1 CAR T targeting pancreatic cell-lines."

CAR T-Cell Therapy • IO biomarker • Preclinical • Oncology • Pancreatic Cancer • Solid Tumor • IL18 • LAG3 • ROR1